SMA treatment Itvisma gets European regulatory panel OK
WHY IT MATTERS
If approved by the European Commission, Itvisma will become available to European SMA patients ages 2+, offering a one-time treatment option that may slow or stop disease progression rather than requiring ongoing infusions.
A European regulatory panel has recommended approval of Itvisma, a one-time gene therapy treatment for spinal muscular atrophy (SMA) in children ages 2 and older. Gene therapy is a type of treatment that fixes problems in a person's genes to help their body work better. The European Commission will make the final decision on whether to approve this treatment for use in Europe.
A European Medicines Agency (EMA) panel recommended that the one-time gene therapy Itvisma (onasemnogene abeparvovec-brve) be approved for patients with spinal muscular atrophy (SMA) ages 2 and older. The Committee for Medicinal Products for Human Use (CHMP) opinion will be reviewed by the European Commission, which has final say over therapy approvals in Europe. The […] The post SMA treatment Itvisma gets European regulatory panel OK appeared first on SMA News Today .
ASK YOUR DOCTOR
If you or your child has SMA in Europe, ask your neurologist about Itvisma's expected availability timeline and whether you might be eligible once the European Commission makes its final decision.